DiscoveryProbe™ DNA Damage/DNA Repair-related Compounds Panel

Compound Panel Contents

Catalog No.	Product Name	Summary	Targets	CAS Number	Smiles
A4605	KU 55933	ATM inhibitor,potent and selective	DNA Damage/DNA Repair|ATM/ATR	587871-26-9	C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4
B1383	VE-822	ATR inhibitor	DNA Damage/DNA Repair|ATM/ATR	1232416-25-9	CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N
A8705	SCR7	DNA ligase IV inhibitor	DNA Damage/DNA Repair|DNA Ligases	1533426-72-0	S=C(NC(/N=C/C1=CC=CC=C1)=C2/N=C/C3=CC=CC=C3)NC2=O
A4083	Rocilinostat (ACY-1215)	Selective HDAC6 inhibitor	DNA Damage/DNA Repair|HDAC	1316214-52-4	C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO
A4090	JNJ-26481585	Potent HDAC inhibitor	DNA Damage/DNA Repair|HDAC	875320-29-9	CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO
A8802	(S)-Crizotinib	Potent MTH1 inhibitor	DNA Damage/DNA Repair|MTH1		CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
A1945	BIBR 1532	Telomerase inhibitor,novel and selective	DNA Damage/DNA Repair|Telomerase	321674-73-1	CC(=CC(=O)NC1=CC=CC=C1C(=O)O)C2=CC3=CC=CC=C3C=C2
A3966	Doxorubicin	Topo II inhibitor,immunosuppresive antineoplastic antibiotic	DNA Damage/DNA Repair|Topoisomerase	23214-92-8	CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O
Download the DNA Damage/DNA Repair-related Compounds Panel - XLSX       Download the DNA Damage/DNA Repair-related Compounds Panel - SDF

Advantages

• Cost-effective and competitive price to save your findings
• Potent, selective and cell-permeable in inhibiting or activating target molecules
• Diverse in chemical structure and route of administration (oral/i.m/i.v injection etc.)
• Detailed files describing potency, selectivity and applications etc.
• Supported by published data from top peer-reviewed journals
• Guaranteed high quality with NMR and HPLC validation

产品描述
A wide range of well-characterized bioactive molecules that covers various targets related to DNA damage/DNA repair, including ATM/ATR, HDAC, and topoisomerase etc. Facilitate your research towards the insights of cancer, genome instability and immune diseases etc. Applicable in cellular assays, animal models and drug screenings etc.
References
1. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012 Jan 18;481(7381):287-94. 
Abstract 
Genomic instability is probably the combined effect of DNA damage, tumour-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells. A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.
2. Park J, Thomas S, Munster PN. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015;7(4):641-52. 
Abstract 
HDAC inhibitors have been approved as single agents for cutaneous and peripheral T-cell lymphoma and have shown promising activity in reversing therapy resistance in other tumor types. This review describes the current understanding on integrating HDAC inhibitors into various immunotherapeutic approaches, such as cancer vaccines, adoptive T-cell transfer and immune checkpoint inhibitors. Furthermore, it summarizes promising treatment strategies in epigenetic immune priming from clinical trials that are currently underway.